Received Jun 13, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| HPV4 | HPV (GARDASIL) | MERCK & CO. INC. | 1 | — | — |
a patient had received 1 dose of the 4-valent HPV vaccine when she was 14, and wanted further guidance regarding completing the dose; No additional AE; This spontaneous report was received from a pharmacist and refers to a 25-year-old female patient. The patient's medical history, concurrent conditions and concomitant therapies were not reported. On an unknown date in approximately 2014, when the patient was 14-year-old, she was vaccinated with 1st dose of quadrivalent human papillomavirus (types 6, 11, 16, 18) recombinant vaccine (GARDASIL) suspension for injection (dose, route of administration, anatomical location, lot # and expiration date were not reported) for prophylaxis. The patient wanted further guidance regarding completing the dose (Inappropriate schedule of product administration). No additional adverse event was reported. Lot# is being requested and will be submitted if received.